Abstract
Paediatric Crohn’s disease is associated with a high disease burden and greater requirement for immunosuppression compared with adult-onset disease. Although anti-tumour necrosis factor therapy can be effective, many patients experience drug failure. Newer biologic and small molecule drugs that have a narrower immunomodulating target have shown promising efficacy in Crohn’s disease, including some in paediatric patients. This article reviews the efficacy and safety of these drugs, as well as common clinical challenges encountered in treating paediatric patients with this condition.
Similar content being viewed by others
References
Mitchel EB, Rosh JR. Pediatric management of Crohn’s disease. Gastroenterol Clin North Am. 2022;51(2):401–24.
Gallagher J, Rosh JR, Sahn B. The future of advanced therapies for pediatric Crohn’s disease. Pediatr Drugs. 2023;25(6):621–33.
Verburgt CM, Ghiboub M, Benninga MA, et al. Nutritional therapy strategies in pediatric Crohn’s disease. Nutrients. 2021;13(1):212.
Walters TD, Kim MO, Denson LA, et al. Increased effectiveness of early therapy with anti-tumor necrosis factor-alpha vs an immunomodulator in children with Crohn’s disease. Gastroenterology. 2014;146(2):383–91.
Aggeletopoulou I, Assimakopoulos SF, Konstantakis C, et al. Interleukin 12/interleukin 23 pathway: biological basis and therapeutic effect in patients with Crohn’s disease. World J Gastroenterol. 2018;24(36):4093–103.
Hyams JS, Dubinsky MC, Baldassano RN. Infliximab is not associated with increased risk of malignancy or hemophagocytic lymphohistiocytosis in pediatric patients with inflammatory bowel disease. Gastroenterology. 2017;152(8):1901-14.e3.
AbbVie Inc. ADALIMUMAB injection, for subcutaneous use: US prescribing information. 2023. https://www.accessdata.fda.gov/. Accessed 07 Feb 2024.
Dayan JR, Dolinger M, Benkov K, et al. Real world experience with ustekinumab in children and young adults at a tertiary care pediatric inflammatory bowel disease center. J Pediatr Gastroenterol Nutr. 2019;69(1):61–7.
Atia O, Shavit-Brunschwig Z, Mould DR, et al. Outcomes, dosing, and predictors of vedolizumab treatment in children with inflammatory bowel disease (VEDOKIDS): a prospective, multicentre cohort study. Lancet Gastroenterol Hepatol. 2023;8(1):31–42.
Sandborn WJ, Rebuck R, Wang Y, et al. Five-year efficacy and safety of ustekinumab treatment in Crohn’s disease: the IM-UNITI trial. Clin Gastroenterol Hepatol. 2022;20(3):578-90.e4.
Hyams JS, Turner D, Cohen SA, et al. Pharmacokinetics, safety and efficacy of intravenous vedolizumab in paediatric patients with ulcerative colitis or Crohn’s disease: results from the phase 2 HUBBLE Study. J Crohns Colitis. 2022;16(8):1243–54.
Rosh JR, Turner D, Griffiths A, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: pharmacokinetics, safety, and efficacy results from UniStar, a phase 1 study. J Crohns Colitis. 2021;15(11):1931–42.
Lee SD, Singla A, Harper J, et al. Tofacitinib appears well tolerated and effective for the treatment of patients with refractory Crohn’s disease. Dig Dis Sci. 2022;67(8):4043–8.
Fenster M, Alayo QA, Khatiwada A, et al. Real-world effectiveness and safety of tofacitinib in Crohn’s disease and IBD-U: a multicenter study from the TROPIC consortium. Clin Gastroenterol Hepatol. 2021;19(10):2207-9.e3.
Panes J, Sandborn WJ, Schreiber S, et al. Tofacitinib for induction and maintenance therapy of Crohn’s disease: results of two phase IIb randomised placebo-controlled trials. Gut. 2017;66(6):1049–59.
Taylor NP. Roche lets go of etro, dumping phase 3 Crohn's prospect 18 months after posting weak colitis data. 2022. https://www.fiercebiotech.com/. Accessed 07 Feb 2024.
Sandborn WJ, Panes J, Danese S, et al. Etrolizumab as induction and maintenance therapy in patients with moderately to severely active Crohn’s disease (BERGAMOT): a randomised, placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol Hepatol. 2023;8(1):43–55.
Schwartz DA, Peyrin-Biroulet L, Lasch K, et al. Efficacy and safety of 2 vedolizumab intravenous regimens for perianal fistulizing Crohn’s disease: ENTERPRISE study. Clin Gastroenterol Hepatol. 2022;20(5):1059-67.e9.
Turner D, Rosh JR, Cohen SA, et al. Ustekinumab in paediatric patients with moderately to severely active Crohn’s disease: results from the UniStar study long-term extension [abstract no. P671]. J Crohns Colitis. 2023;17(Suppl 1):i802–3.
Yerushalmy-Feler A, Pujol-Muncunill G, Martin-de-Carpi J, et al. Safety and potential efficacy of escalating dose of ustekinumab in pediatric Crohn disease (the Speed-up study): a multicenter study from the Pediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr. 2022;75(6):717–23.
Attauabi M, Burisch J, Seidelin JB. Efficacy of ustekinumab for active perianal fistulizing Crohn’s disease: a systematic review and meta-analysis of the current literature. Scand J Gastroenterol. 2021;56(1):53–8.
AbbVie Inc. SKYRIZI (risankizumab-rzaa) injection, for subcutaneous or intravenous use: US prescribing information. 2023. https://dailymed.nlm.nih.gov/. Accessed 07 Feb 2024.
D’Haens G, Panaccione R, Baert F, et al. Risankizumab as induction therapy for Crohn’s disease: results from the phase 3 ADVANCE and MOTIVATE induction trials. Lancet. 2022;399(10340):2015–30.
Ferrante M, Panaccione R, Baert F, et al. Risankizumab as maintenance therapy for moderately to severely active Crohn’s disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial. Lancet. 2022;399(10340):2031–46.
Fumery M, Defrance A, Roblin X, et al. Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn’s disease: a GETAID multicentre cohort study. Aliment Pharmacol Ther. 2023;57(4):426–34.
Sandborn WJ, D’Haens GR, Reinisch W, et al. Guselkumab for the treatment of Crohn’s disease: induction results from the phase 2 GALAXI-1 study. Gastroenterology. 2022;162(6):1650-64.e8.
Sands BE, Peyrin-Biroulet L, Kierkus J, et al. Efficacy and safety of mirikizumab in a randomized phase 2 study of patients with Crohn’s disease. Gastroenterology. 2022;162(2):495–508.
Collen LV. Rapid clinical remission with upadacitinib in a pediatric patient with refractory Crohn’s disease. Inflamm Bowel Dis. 2023;29(7):1175–6.
Loftus EV, Panes J, Lacerda AP, et al. Upadacitinib induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2023;388(21):1966–80.
D’Haens G, Panes J, Louis E, et al. Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn’s disease in the CELEST extension study. Clin Gastroenterol Hepatol. 2022;20(10):2337-46.e3.
Sandborn WJ, Feagan BG, Loftus EV, et al. Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn’s disease. Gastroenterology. 2020;158(8):2123–38.e8.
Vermeire S, Schreiber S, Petryka R, et al. Clinical remission in patients with moderate-to-severe Crohn’s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial. Lancet. 2017;389(10066):266–75.
D’Haens GR, Lee S, Taylor SA, et al. Filgotinib for the treatment of small bowel Crohn’s disease: the DIVERGENCE 1 trial. Gastroenterology. 2023;165(1):289–92.e3.
Feagan BG, Sandborn WJ, Danese S, et al. Ozanimod induction therapy for patients with moderate to severe Crohn’s disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol. 2020;5(9):8119–828.
Ahmed W, Galati J, Kumar A, et al. Dual biologic or small molecule therapy for treatment of inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022;20(3):e361–79.
Dolinger MT, Spencer EA, Lai J, et al. Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease. Inflamm Bowel Dis. 2021;27:1210–4.
Wlazlo M, Meglicka M, Wiernicka A, et al. Dual biologic therapy in moderate to severe pediatric inflammatory bowel disease: a retrospective study. Children (Basel). 2022;10(1):11.
Lightner AL, Otero-Pineiro A, Reese J, et al. A phase I study of ex vivo expanded allogeneic bone marrow-derived mesenchymal stem cells for the treatment of pediatric perianal fistulizing Crohn’s disease. Inflamm Bowel Dis. 2023;29(12):1912–9.
Garcia-Olmo D, Gilaberte I, Binek M, et al. Follow-up study to evaluate the long-term safety and efficacy of darvadstrocel (mesenchymal stem cell treatment) in patients with perianal fistulizing Crohn’s disease: ADMIRE-CD phase 3 randomized controlled trial. Dis Colon Rectum. 2022;65(5):713–20.
Vieujean S, Loly JP, Boutaffala L, et al. Mesenchymal stem cell injection in Crohn’s disease strictures: a phase I-II clinical study. J Crohns Colitis. 2022;16(3):506–10.
Green MS, Purohi M, Sadacharam K, et al. Efficacy of hyperbaric oxygen in patients with Crohn’s disease: two case reports. Undersea Hyperb Med. 2013;40(2):201–4.
Kante B, Sahu P, Kedia S, et al. Efficacy and tolerability of hyperbaric oxygen therapy in small bowel stricturing Crohn’s disease: a pilot study. Intest Res. 2022;20(2):231–9.
Lansdorp CA, Gecse KB, Buskens CJ, et al. Hyperbaric oxygen therapy for the treatment of perianal fistulas in 20 patients with Crohn’s disease. Aliment Pharmacol Ther. 2021;53(5):587–97.
Lansdorp CA, Buskens CJ, Gecse KB, et al. Hyperbaric oxygen therapy for the treatment of rectovaginal fistulas in patients with Crohn’s disease: results of the HOT-REVA pilot study. BJS Open. 2021;5(3):zrab042.
Dulai PS, Gleeson MW, Taylor D, et al. Systematic review: the safety and efficacy of hyperbaric oxygen therapy for inflammatory bowel disease. Aliment Pharmacol Ther. 2014;39(11):1266–75.
Lee D, Baldassano RN, Otley AR, et al. Comparative effectiveness of nutritional and biological therapy in North American children with active Crohn’s disease. Inflamm Bowel Dis. 2015;21(8):1786–93.
Chen JM, He LW, Yan T, et al. Oral exclusive enteral nutrition induces mucosal and transmural healing in patients with Crohn’s disease. Gastroenterol Rep (Oxf). 2019;7(3):176–84.
Levine A, Wine E, Assa A, et al. Crohn’s disease exclusion diet plus partial enteral nutrition induces sustained remission in a randomized controlled trial. Gastroenterology. 2019;157(2):440-50.e8.
Cohen SA, Gold BD, Oliva S, et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2014;59(4):516–21.
Suskind DL, Lee D, Kim YM, et al. The specific carbohydrate diet and diet modification as induction therapy for pediatric Crohn’s disease: a randomized diet controlled trial. Nutrients. 2020;12(12):3749.
Lewis JD, Sandler RS, Brotherton C, et al. A randomized trial comparing the specific carbohydrate diet to a Mediterranean diet in adults with Crohn’s disease. Gastroenterology. 2021;161(3):837-52.e9.
Svolos V, Hansen R, Nichols B, et al. Treatment of active Crohn’s disease with an ordinary food-based diet that replicates exclusive enteral nutrition. Gastroenterology. 2019;156(5):1354-67.e6.
Sinniger V, Pellissier S, Fauvelle F, et al. A 12-month pilot study outcomes of vagus nerve stimulation in Crohn’s disease. Neurogastroenterol Motil. 2020;32(10):e13911.
Sahn B, Pascuma K, Kohn N, et al. Transcutaneous auricular vagus nerve stimulation attenuates inflammatory bowel disease in children: a proof-of-concept clinical trial. Bioelectron Med. 2023;9(1):23.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The preparation of this review was not supported by any external funding.
Authorship and conflict of interest
T. Nie is a salaried employee of Adis International Ltd/Springer Nature and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.
Ethics approval, Consent to participate, Consent for publication, Availability of data and material, Code availability
Not applicable.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Nie, T. Treating paediatric Crohn’s disease is challenging but new treatments hold promise. Drugs Ther Perspect 40, 121–126 (2024). https://doi.org/10.1007/s40267-024-01056-x
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40267-024-01056-x